| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we studied the oncogenic role of semaphorin 3A to establish the novel therapeutic strategy against lung cancer. Inhibition of semaphorin 3A signaling by shRNA system in lung cancer cells decreased their proliferative capacity and increased the sensitivity to EGFR inhibitors. Furthermore, the self-renewal or tumorigenic capacity of cancer stem-like cells, the origin of cancer, was completely abolished by the inhibition of semaphorin 3A signaling. These results demonstrate that the inhibition of semaphorin 3A signaling not only releases the resistance to several drugs but also eradicates cancer stem-like cell in lung cancer.
|
